# Correction to “Farber's Lipogranulomatosis: Multimodal Therapy With Tocilizumab and Consolidative HSCT Improves Assessment, and Long‐Term Outcome”

PMC · DOI: 10.1002/jmd2.70049 · JIMD Reports · 2025-11-10

## Full-text entities

- **Diseases:** Farber's Lipogranulomatosis (MESH:D055577)
- **Chemicals:** Tocilizumab (MESH:C502936)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12602454/full.md

---
Source: https://tomesphere.com/paper/PMC12602454